According to a research report released by Zhongtai Securities, several CRO and CDMO companies deployed AI in the first three quarters of 2026. For example, Pharmaceutical and Kangde's testing business accelerated “HI+AI” integration to meet the rapidly growing dry and wet closed-loop demand from AI4S customers around the world, the Zhaoyan New Drug AI pathology reading and organoid platform was expanding towards the front end of drug discovery, and the increase in AI candidate molecules directly drove security assessment demand. It is expected that as the AIDD project continues to expand to the back end, it is expected to bring strong growth momentum to the sector in the medium to long term.

According to a research report released by Zhongtai Securities, several CRO and CDMO companies deployed AI in the first three quarters of 2026. For example, Pharmaceutical and Kangde's testing business accelerated “HI+AI” integration to meet the rapidly growing dry and wet closed-loop demand from AI4S customers around the world, the Zhaoyan New Drug AI pathology reading and organoid platform was expanding towards the front end of drug discovery, and the increase in AI candidate molecules directly drove security assessment demand. It is expected that as the AIDD project continues to expand to the back end, it is expected to bring strong growth momentum to the sector in the medium to long term.